|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OXCT1 |
Gene summary for OXCT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OXCT1 | Gene ID | 5019 |
| Gene name | 3-oxoacid CoA-transferase 1 | |
| Gene Alias | OXCT | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | A0A024R040 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5019 | OXCT1 | P22T-E | Human | Esophagus | ESCC | 1.58e-05 | 7.54e-02 | 0.1236 |
| 5019 | OXCT1 | P23T-E | Human | Esophagus | ESCC | 1.64e-07 | 2.54e-01 | 0.108 |
| 5019 | OXCT1 | P24T-E | Human | Esophagus | ESCC | 1.35e-15 | 3.80e-01 | 0.1287 |
| 5019 | OXCT1 | P26T-E | Human | Esophagus | ESCC | 3.22e-11 | 1.75e-01 | 0.1276 |
| 5019 | OXCT1 | P27T-E | Human | Esophagus | ESCC | 1.05e-32 | 7.22e-01 | 0.1055 |
| 5019 | OXCT1 | P28T-E | Human | Esophagus | ESCC | 5.06e-09 | 2.85e-01 | 0.1149 |
| 5019 | OXCT1 | P30T-E | Human | Esophagus | ESCC | 9.09e-09 | 3.92e-01 | 0.137 |
| 5019 | OXCT1 | P31T-E | Human | Esophagus | ESCC | 1.58e-18 | 3.14e-01 | 0.1251 |
| 5019 | OXCT1 | P32T-E | Human | Esophagus | ESCC | 1.20e-47 | 1.01e+00 | 0.1666 |
| 5019 | OXCT1 | P36T-E | Human | Esophagus | ESCC | 2.26e-04 | 2.23e-01 | 0.1187 |
| 5019 | OXCT1 | P37T-E | Human | Esophagus | ESCC | 1.46e-27 | 6.73e-01 | 0.1371 |
| 5019 | OXCT1 | P39T-E | Human | Esophagus | ESCC | 4.68e-08 | 1.20e-01 | 0.0894 |
| 5019 | OXCT1 | P40T-E | Human | Esophagus | ESCC | 2.90e-03 | 1.33e-01 | 0.109 |
| 5019 | OXCT1 | P42T-E | Human | Esophagus | ESCC | 3.39e-07 | 1.25e-01 | 0.1175 |
| 5019 | OXCT1 | P44T-E | Human | Esophagus | ESCC | 2.34e-07 | 2.27e-01 | 0.1096 |
| 5019 | OXCT1 | P47T-E | Human | Esophagus | ESCC | 6.46e-17 | 2.43e-01 | 0.1067 |
| 5019 | OXCT1 | P48T-E | Human | Esophagus | ESCC | 1.04e-13 | 3.38e-01 | 0.0959 |
| 5019 | OXCT1 | P52T-E | Human | Esophagus | ESCC | 4.63e-17 | 4.10e-01 | 0.1555 |
| 5019 | OXCT1 | P54T-E | Human | Esophagus | ESCC | 1.72e-34 | 8.93e-01 | 0.0975 |
| 5019 | OXCT1 | P56T-E | Human | Esophagus | ESCC | 2.84e-11 | 1.15e+00 | 0.1613 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:000758410 | Esophagus | ESCC | response to nutrient | 114/8552 | 174/18723 | 9.43e-08 | 1.56e-06 | 114 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| GO:0097305111 | Esophagus | ESCC | response to alcohol | 138/8552 | 253/18723 | 2.70e-03 | 1.14e-02 | 138 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:0009743111 | Esophagus | ESCC | response to carbohydrate | 135/8552 | 253/18723 | 8.16e-03 | 2.89e-02 | 135 |
| GO:005070810 | Esophagus | ESCC | regulation of protein secretion | 142/8552 | 268/18723 | 9.31e-03 | 3.24e-02 | 142 |
| GO:005071416 | Esophagus | ESCC | positive regulation of protein secretion | 76/8552 | 137/18723 | 1.32e-02 | 4.31e-02 | 76 |
| GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa002809 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
| hsa0028014 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
| hsa002808 | Oral cavity | OSCC | Valine, leucine and isoleucine degradation | 30/3704 | 48/8465 | 6.75e-03 | 1.57e-02 | 7.99e-03 | 30 |
| hsa0028013 | Oral cavity | OSCC | Valine, leucine and isoleucine degradation | 30/3704 | 48/8465 | 6.75e-03 | 1.57e-02 | 7.99e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OXCT1 | SNV | Missense_Mutation | c.1497N>T | p.Gln499His | p.Q499H | P55809 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OXCT1 | SNV | Missense_Mutation | c.1064N>A | p.Arg355Gln | p.R355Q | P55809 | protein_coding | tolerated(0.51) | benign(0.03) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OXCT1 | SNV | Missense_Mutation | novel | c.1033N>C | p.Asn345His | p.N345H | P55809 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OXCT1 | SNV | Missense_Mutation | c.1551N>C | p.Gln517His | p.Q517H | P55809 | protein_coding | deleterious(0.03) | possibly_damaging(0.775) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| OXCT1 | SNV | Missense_Mutation | novel | c.1560T>G | p.Asn520Lys | p.N520K | P55809 | protein_coding | tolerated_low_confidence(0.06) | benign(0.006) | TCGA-OL-A5RY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OXCT1 | deletion | Frame_Shift_Del | novel | c.1139delN | p.Phe380SerfsTer9 | p.F380Sfs*9 | P55809 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| OXCT1 | SNV | Missense_Mutation | novel | c.1490A>G | p.Asp497Gly | p.D497G | P55809 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| OXCT1 | SNV | Missense_Mutation | novel | c.94T>C | p.Phe32Leu | p.F32L | P55809 | protein_coding | tolerated(0.13) | benign(0.012) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| OXCT1 | SNV | Missense_Mutation | rs766119402 | c.854N>A | p.Arg285Gln | p.R285Q | P55809 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OXCT1 | SNV | Missense_Mutation | c.1254G>C | p.Lys418Asn | p.K418N | P55809 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3955-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | capecitabine | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |